ABBV-295
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
AbbVie · Phase 1 · Active, not recruiting · Enrollment 80
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| ABBV-295 or Placebo-Group 1 | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 2 | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 3 | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 3 Extension | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 4 | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 4 Extension | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 5 | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 6 | n/r | n/r | n/r | n/r |
Not shown
- ABBV-295 or Placebo-Group 1: endpoint not reported
- ABBV-295 or Placebo-Group 2: endpoint not reported
- ABBV-295 or Placebo-Group 3: endpoint not reported
- ABBV-295 or Placebo-Group 3 Extension: endpoint not reported
- ABBV-295 or Placebo-Group 4: endpoint not reported
- ABBV-295 or Placebo-Group 4 Extension: endpoint not reported
- ABBV-295 or Placebo-Group 5: endpoint not reported
- ABBV-295 or Placebo-Group 6: endpoint not reported